生存期-话题@MedSci

#生存期#

350篇内容 | 2801人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378248, encodeId=1bec13e8248f6, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Acta Neuropathologica：DNA甲基化年龄的加速与肌萎缩侧索硬化发病年龄和生存期有关, objectType=article, longId=198368, objectId=179b1983687c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=179b1983687c, replyNumber=0, likeNumber=61, createdTime=2020-07-31, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=179b1983687c, moduleTitle=Acta Neuropathologica：DNA甲基化年龄的加速与肌萎缩侧索硬化发病年龄和生存期有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=179b1983687c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Brit J Heamatol：血清BDNF浓度预测多发性骨髓瘤患者的多发性神经病和总生存期, objectType=article, longId=196878, objectId=8a431968e8b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a431968e8b4, replyNumber=0, likeNumber=82, createdTime=2020-07-03, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a431968e8b4, moduleTitle=Brit J Heamatol：血清BDNF浓度预测多发性骨髓瘤患者的多发性神经病和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a431968e8b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378246, encodeId=cb4713e82467f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, objectType=article, longId=195300, objectId=951f1953003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951f1953003d, replyNumber=0, likeNumber=57, createdTime=2020-06-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951f1953003d, moduleTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=951f1953003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378245, encodeId=bfa013e8245e3, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=55, createdTime=2020-05-19, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378244, encodeId=01f513e82447d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Oncol：PD-L1及CTLA-4双重抑制或可改善晚期结肠癌患者生存期, objectType=article, longId=194071, objectId=0c321940e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c321940e154, replyNumber=0, likeNumber=75, createdTime=2020-05-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c321940e154, moduleTitle=JAMA Oncol：PD-L1及CTLA-4双重抑制或可改善晚期结肠癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c321940e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378243, encodeId=30c113e8243ae, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, objectType=article, longId=192958, objectId=e2db19295879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2db19295879, replyNumber=0, likeNumber=57, createdTime=2020-04-27, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2db19295879, moduleTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2db19295879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378242, encodeId=89c813e8242b8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Surg：肿瘤破裂是影响局限性胃肠道间质瘤患者术后生存期的重要因素, objectType=article, longId=191693, objectId=5abf19169347, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5abf19169347, replyNumber=0, likeNumber=66, createdTime=2020-04-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5abf19169347, moduleTitle=JAMA Surg：肿瘤破裂是影响局限性胃肠道间质瘤患者术后生存期的重要因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5abf19169347)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378241, encodeId=799213e824196, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长, objectType=article, longId=189951, objectId=cadc189951ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cadc189951ee, replyNumber=0, likeNumber=88, createdTime=2020-03-15, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cadc189951ee, moduleTitle=中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cadc189951ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378240, encodeId=26f013e82403f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=胶质母细胞瘤进展：新途径可避开血脑屏障,显著延长生存期, objectType=article, longId=186544, objectId=746518654438, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=746518654438, replyNumber=0, likeNumber=49, createdTime=2020-01-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=746518654438, moduleTitle=胶质母细胞瘤进展：新途径可避开血脑屏障,显著延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=746518654438)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378239, encodeId=3f4f13e823985, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Nature：胶质母细胞瘤进展，新途径可避开血脑屏障,显著延长生存期！, objectType=article, longId=186535, objectId=9e3518653506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e3518653506, replyNumber=0, likeNumber=52, createdTime=2020-01-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e3518653506, moduleTitle=Nature：胶质母细胞瘤进展，新途径可避开血脑屏障,显著延长生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e3518653506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378238, encodeId=7d9313e823815, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期, objectType=article, longId=186076, objectId=871f1860e69e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=871f1860e69e, replyNumber=0, likeNumber=68, createdTime=2020-01-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=871f1860e69e, moduleTitle=Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=871f1860e69e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378237, encodeId=83ff13e82377b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Hypertension：高血压成年人叶酸治疗对无卒中生存期的影响, objectType=article, longId=185163, objectId=2bb818516380, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bb818516380, replyNumber=0, likeNumber=71, createdTime=2019-12-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bb818516380, moduleTitle=Hypertension：高血压成年人叶酸治疗对无卒中生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bb818516380)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=184850, objectId=079b184850dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=079b184850dc, replyNumber=0, likeNumber=86, createdTime=2019-12-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=079b184850dc, moduleTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=079b184850dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378235, encodeId=2c5713e82351d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , objectType=article, longId=184672, objectId=90f01846e265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f01846e265, replyNumber=0, likeNumber=75, createdTime=2019-12-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f01846e265, moduleTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90f01846e265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378234, encodeId=41e913e82347d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：Ribociclib+氟维司群可改善晚期乳腺癌患者生存期, objectType=article, longId=184669, objectId=d9291846690b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9291846690b, replyNumber=0, likeNumber=59, createdTime=2019-12-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9291846690b, moduleTitle=NEJM：Ribociclib+氟维司群可改善晚期乳腺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9291846690b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378233, encodeId=dcd413e823384, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, objectType=article, longId=184023, objectId=8e3e1840235e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3e1840235e, replyNumber=0, likeNumber=124, createdTime=2019-12-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3e1840235e, moduleTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3e1840235e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378232, encodeId=b53913e823272, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Chest：70岁以下系统性硬化相关肺动脉高压患者生存期有所改善, objectType=article, longId=183327, objectId=9fc218332ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fc218332ee7, replyNumber=0, likeNumber=68, createdTime=2019-11-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fc218332ee7, moduleTitle=Chest：70岁以下系统性硬化相关肺动脉高压患者生存期有所改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fc218332ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378231, encodeId=b50b13e823117, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, objectType=article, longId=183027, objectId=fd5a18302e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5a18302e46, replyNumber=0, likeNumber=90, createdTime=2019-11-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5a18302e46, moduleTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5a18302e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378230, encodeId=892813e823057, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=一线治疗显著改善广泛期小细胞肺癌患者的总生存期, objectType=article, longId=181036, objectId=bfa3181036ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfa3181036ef, replyNumber=0, likeNumber=54, createdTime=2019-10-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfa3181036ef, moduleTitle=一线治疗显著改善广泛期小细胞肺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfa3181036ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378229, encodeId=d71d13e822942, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, objectType=article, longId=180568, objectId=34561805686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34561805686b, replyNumber=0, likeNumber=71, createdTime=2019-10-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34561805686b, moduleTitle=2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34561805686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Acta Neuropathologica：DNA甲基化年龄的加速与肌萎缩侧索硬化发病年龄和生存期有关

2020-07-31

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Brit J Heamatol：血清BDNF浓度预测多发性骨髓瘤患者的多发性神经病和总生存期

2020-07-03

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！

2020-06-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2020-05-19

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA Oncol：PD-L1及CTLA-4双重抑制或可改善晚期结肠癌患者生存期

2020-05-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期

2020-04-27

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA Surg：肿瘤破裂是影响局限性胃肠道间质瘤患者术后生存期的重要因素

2020-04-09

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长

2020-03-15

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

胶质母细胞瘤进展：新途径可避开血脑屏障,显著延长生存期

2020-01-21

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Nature：胶质母细胞瘤进展，新途径可避开血脑屏障,显著延长生存期！

2020-01-21

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期

2020-01-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Hypertension：高血压成年人叶酸治疗对无卒中生存期的影响

2019-12-26

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

2019-12-18

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 

2019-12-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

NEJM：Ribociclib+氟维司群可改善晚期乳腺癌患者生存期

2019-12-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期

2019-12-04

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Chest：70岁以下系统性硬化相关肺动脉高压患者生存期有所改善

2019-11-22

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期

2019-11-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

一线治疗显著改善广泛期小细胞肺癌患者的总生存期

2019-10-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2019 ESMO：PD-L1单抗Atezolizumab联合化疗延长了晚期小细胞肺癌的生存期

2019-10-07

科室
- - 订阅+
  - 更多科室
工具
服务